Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid‐Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is the most refractory hematologic malignancy characterized by acute onset, rapid progression, and high recurrence rate. Here, codelivery of BCL2 (ABT199) and MCL1 (TW37) inhibitors using phenylboronic acid‐functionalized polypeptide nanovehicles to achieve synergetic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jiguo, Zhao, Xiaofei, Zhang, Peng, Zhang, Yueyue, Cheng, Ru, Zhong, Zhiyuan, Deng, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015845/
https://www.ncbi.nlm.nih.gov/pubmed/36683178
http://dx.doi.org/10.1002/advs.202204866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015845/
https://www.ncbi.nlm.nih.gov/pubmed/36683178
http://dx.doi.org/10.1002/advs.202204866

Ejemplares similares